Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | EVP, Operations & Program Mana | January 19, 2021 | January 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date January 19, 2021 · Filed January 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,000 |
Reported balance
After 2021-01-19 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2021-01-19 · Exercise / conversion · Acquired 2,000 · Balance 12,000 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 35,000 |
Reported balance
After 2021-01-19 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2021-01-19 · Exercise / conversion · Disposed 23,000 · Balance 35,000 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2021-01-19 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2021-01-19 · Sale · Disposed 25,000 · Balance 10,000 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2023-11-03 | Direct | 0 |
Reported balance
After 2021-01-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-01-19 · Exercise / conversion · Disposed 2,000 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.07 · Expires 2025-04-17 | Direct | 27,000 |
Reported balance
After 2021-01-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-01-19 · Exercise / conversion · Disposed 23,000 · Balance 27,000 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3: The option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy Ryan Hill (son) | 500 |
Reported balance
Holding disclosure · report date 2021-01-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 500 F2: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Brandon Hill (son) | 400 |
Reported balance
Holding disclosure · report date 2021-01-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 400 F2: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Connor Hill (son) | 300 |
Reported balance
Holding disclosure · report date 2021-01-19 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 300 F2: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.
F2: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
F3: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · derivative · entry 8 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 23,000 shares Expires 2025-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · derivative · entry 7 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 25,000 | $69.00 | $1,725,000.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · nonDerivative · entry 3 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 23,000 | $4.07 | $93,610.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,000 | $0.84 | $1,680.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 57,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-065104 · doc4.xml · derivative · entry 7 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 57,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 20,486 | $64.06 | $1,312,333.16 |
DisclosureSEC source: 0001209191-20-065104 · doc4.xml · nonDerivative · entry 3 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.79 to 64.58, inclusive. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 36,514 | $63.52 | $2,319,369.28 |
DisclosureSEC source: 0001209191-20-065104 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,486 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.79 to 63.785, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 57,000 | $0.84 | $47,880.00 |
DisclosureSEC source: 0001209191-20-065104 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-063933 · doc4.xml · derivative · entry 6 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 40,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 40,000 | $59.00 | $2,360,000.00 |
DisclosureSEC source: 0001209191-20-063933 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 40,000 | $0.84 | $33,600.00 |
DisclosureSEC source: 0001209191-20-063933 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-045396 · doc4.xml · derivative · entry 6 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 Underlying: Common Stock · 1,600 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,600 | $37.37 | $59,792.00 |
DisclosureSEC source: 0001209191-20-045396 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,600 | $0.84 | $1,344.00 |
DisclosureSEC source: 0001209191-20-045396 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,400 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-042221 · doc4.xml · derivative · entry 6 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,600 Underlying: Common Stock · 17,400 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 17,400 | $49.00 | $852,600.00 |
DisclosureSEC source: 0001209191-20-042221 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.00 to 49.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 17,400 | $0.84 | $14,616.00 |
DisclosureSEC source: 0001209191-20-042221 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-040676 · doc4.xml · derivative · entry 7 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 3,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,200 | $48.01 | $57,612.00 |
DisclosureSEC source: 0001209191-20-040676 · doc4.xml · nonDerivative · entry 3 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.67 to 48.20, inclusive. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,800 | $47.03 | $84,654.00 |
DisclosureSEC source: 0001209191-20-040676 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.66 to 47.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,000 | $0.84 | $2,520.00 |
DisclosureSEC source: 0001209191-20-040676 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-038660 · doc4.xml · derivative · entry 7 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,000 Underlying: Common Stock · 19,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 14,694 | $45.38 | $666,813.72 |
DisclosureSEC source: 0001209191-20-038660 · doc4.xml · nonDerivative · entry 3 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.00 to 45.54, inclusive. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,306 | $44.66 | $192,305.96 |
DisclosureSEC source: 0001209191-20-038660 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,694 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.08 to 44.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 19,000 | $0.84 | $15,960.00 |
DisclosureSEC source: 0001209191-20-038660 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 07:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009860 · doc4.xml · derivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-002419 · doc4.xml · derivative · entry 6 HILL NANCY LOUISE · CIK 0001780790 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 60,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 60,000 | $29.14 | $1,748,400.00 |
DisclosureSEC source: 0001209191-20-002419 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.55 to 29.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 60,000 | $0.84 | $50,400.00 |
DisclosureSEC source: 0001209191-20-002419 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:50 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | PurchaseCommon Stock | 300 | $20.00 | $6,000.00 |
DisclosureSEC source: 0001572426-19-000091 · edgar.xml · nonDerivative · entry 4 HILL NANCY LOUISE · CIK 0001780790 · Sr Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Connor Hill (son) Disclosed balance after: 300 F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:50 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | PurchaseCommon Stock | 400 | $20.00 | $8,000.00 |
DisclosureSEC source: 0001572426-19-000091 · edgar.xml · nonDerivative · entry 3 HILL NANCY LOUISE · CIK 0001780790 · Sr Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Brandon Hill (son) Disclosed balance after: 400 F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:50 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | PurchaseCommon Stock | 500 | $20.00 | $10,000.00 |
DisclosureSEC source: 0001572426-19-000091 · edgar.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · Sr Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Ryan Hill (son) Disclosed balance after: 500 F1 · shares: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:50 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | PurchaseCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001572426-19-000091 · edgar.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · Sr Vice President, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.